Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | PRKCA | P17252 | 4/20 | 0.74 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.74 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.74 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.74 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.65 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.65 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30082778 | 1.00 | ALDH1A1 (0.81) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL896399 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| Tripalmitin SCHEMBL3239772 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL8908785 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL24334742 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL24334040 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL24333834 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL24333843 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL22973398 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL23612380 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275046-A1 | Noval Surfactants and Applications Thereof | TS PHARMA (FR) | 2007-11-29 | — | — | US | disclosed |
| EP-1708993-A2 | NOVEL SURFACTANTS AND APPLICATIONS THEREOF | TS Pharma (FR) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005040105-A2 | NOVEL SURFACTANTS AND APPLICATIONS THEREOF | TS PHARMA (FR) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275046-A1 | Noval Surfactants and Applications Thereof | SGMS1, SGMS2, ANXA6 | ALDH1A1 3574/4885LMNA 1160/4885PRKCA 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.